NCT03631862

Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Status unknown Phase 4 Last updated 15 August 2018

What this trial tests

Phase 4 trial testing Apatinib in Newly Diagnosed Peripheral T-cell Lymphoma in 100 participants. Status unknown.

Timeline

1 September 2018

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Zhengzhou University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 September 2018
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across China

Drugs / interventions tested

• Apatinib (Apatinib) — full drug profile →
• CHOP Regimen

Conditions studied

• Newly Diagnosed Peripheral T-cell Lymphoma — all drugs for Newly Diagnosed Peripheral T-cell Lymphoma →

Sponsor

Zhengzhou University

Who can join

Adults 14 to 70, any sex, with Newly Diagnosed Peripheral T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of Apatinib Combined With CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell lymphoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma.
   Xie C, Li X, Zeng H, Qian W. · · 2020 · cited 18× · PMID 33292562 · DOI 10.1186/s40164-020-00188-w
2. Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine.
   Zhang Y, Lee D, Brimer T, Hussaini M, et al · · 2020 · cited 11× · PMID 32637355 · DOI 10.3389/fonc.2020.00898